HRTX Financial Statements

Balance sheet, income statement, cash flow, and dividends for Heron Therapeutics Inc (HRTX).


$232.71M Market Cap.

As of 02/28/2025 5:00 PM ET (MRY) • Disclaimer

HRTX Market Cap. (MRY)


HRTX Shares Outstanding (MRY)


HRTX Assets (MRY)


Total Assets

$233.15M

Total Liabilities

$266.80M

Total Investments

$33.48M

HRTX Income (MRY)


Revenue

$144.28M

Net Income

-$13.58M

Operating Expense

$117.17M

HRTX Cash Flow (MRY)


CF Operations

-$22.53M

CF Investing

$18.71M

CF Financing

$940.00K

HRTX Dividends (MRY)


Period

Dividends

Yield %

Growth %

Payout Ratio

Coverage Ratio

2024

$0

0%

0%

0%

-

2023

$0

0%

0%

0%

-

2022

$0

0%

0%

0%

-

2021

$0

0%

0%

0%

-

2020

$0

0%

-

0%

-

HRTX Balance Sheet (MRY)


Metric

2024

2023

2022

2021

Total Assets

$233,147,000 (4.78%)

$222,506,000 (-11.33%)

$250,951,000 (-17.91%)

$305,706,000 (-13.53%)

Assets Current

$209,014,000 (10.72%)

$188,774,000 (-8.11%)

$205,435,000 (-19.25%)

$254,423,000 (-19.02%)

Assets Non-Current

$24,133,000 (-28.46%)

$33,732,000 (-25.89%)

$45,516,000 (-11.25%)

$51,283,000 (30.29%)

Goodwill & Intangible Assets

$0 (0%)

$0 (0%)

$0 (0%)

$0 (0%)

Shareholders Equity

-$33,651,000 (0.95%)

-$33,973,000 (-350.32%)

$13,572,000 (-82.50%)

$77,570,000 (-67.20%)

Property Plant & Equipment Net

$17,650,000 (-31.07%)

$25,604,000 (-14.09%)

$29,805,000 (-11.20%)

$33,563,000 (-13.97%)

Cash & Equivalents

$25,802,000 (-10.03%)

$28,677,000 (86.65%)

$15,364,000 (-83.03%)

$90,541,000 (-13.88%)

Accumulated Other Comprehensive Income

$13,000 (0.00%)

$13,000 (168.42%)

-$19,000 (-216.67%)

-$6,000 (-102.33%)

Deferred Revenue

$0 (0%)

$0 (0%)

$0 (0%)

$0 (0%)

Total Investments

$33,481,000 (-35.28%)

$51,732,000 (-25.55%)

$69,488,000 (3.65%)

$67,039,000 (-35.14%)

Investments Current

$33,481,000 (-35.28%)

$51,732,000 (-25.55%)

$69,488,000 (3.65%)

$67,039,000 (-35.14%)

Investments Non-Current

$0 (0%)

$0 (0%)

$0 (0%)

$0 (0%)

Inventory

$53,160,000 (26.24%)

$42,110,000 (-22.84%)

$54,573,000 (12.80%)

$48,382,000 (15.46%)

Trade & Non-Trade Receivables

$78,881,000 (31.17%)

$60,137,000 (15.54%)

$52,049,000 (46.62%)

$35,499,000 (-15.18%)

Trade & Non-Trade Payables

$11,709,000 (261.39%)

$3,240,000 (0.47%)

$3,225,000 (-15.20%)

$3,803,000 (624.38%)

Accumulated Retained Earnings (Deficit)

-$1,919,594,000 (-0.71%)

-$1,906,014,000 (-6.16%)

-$1,795,455,000 (-11.28%)

-$1,613,431,000 (-15.85%)

Tax Assets

$0 (0%)

$0 (0%)

$0 (0%)

$0 (0%)

Tax Liabilities

$0 (0%)

$0 (0%)

$0 (0%)

$0 (0%)

Total Debt

$177,763,000 (-1.04%)

$179,628,000 (14.07%)

$157,477,000 (-1.27%)

$159,495,000 (548.06%)

Debt Current

$3,037,000 (-1.24%)

$3,075,000 (14.14%)

$2,694,000 (11.46%)

$2,417,000 (-75.95%)

Debt Non-Current

$174,726,000 (-1.03%)

$176,553,000 (14.06%)

$154,783,000 (-1.46%)

$157,078,000 (978.76%)

Total Liabilities

$266,798,000 (4.02%)

$256,479,000 (8.05%)

$237,379,000 (4.05%)

$228,136,000 (94.88%)

Liabilities Current

$91,457,000 (14.77%)

$79,685,000 (-3.24%)

$82,355,000 (15.90%)

$71,058,000 (-30.68%)

Liabilities Non-Current

$175,341,000 (-0.82%)

$176,794,000 (14.04%)

$155,024,000 (-1.31%)

$157,078,000 (978.76%)

HRTX Income Statement (MRY)


Metric

2024

2023

2022

2021

Revenues

$144,285,000 (13.57%)

$127,044,000 (17.99%)

$107,672,000 (24.70%)

$86,346,000 (-2.59%)

Cost of Revenue

$38,648,000 (-40.64%)

$65,105,000 (18.64%)

$54,874,000 (19.24%)

$46,021,000 (27.17%)

Selling General & Administrative Expense

$100,482,000 (-13.87%)

$116,657,000 (-2.75%)

$119,950,000 (-5.80%)

$127,332,000 (20.04%)

Research & Development Expense

$16,683,000 (-70.15%)

$55,897,000 (-48.01%)

$107,506,000 (-17.82%)

$130,821,000 (-25.05%)

Operating Expenses

$117,165,000 (-32.10%)

$172,554,000 (-26.25%)

$233,986,000 (-9.67%)

$259,031,000 (-7.69%)

Interest Expense

$2,482,000 (392.46%)

$504,000 (-39.71%)

$836,000 (-57.71%)

$1,977,000 (214.15%)

Income Tax Expense

$0 (0%)

$0 (0%)

$0 (0%)

$0 (0%)

Net Loss Income from Discontinued Operations

$0 (0%)

$0 (0%)

$0 (0%)

$0 (0%)

Consolidated Income

-$13,580,000 (87.72%)

-$110,559,000 (39.26%)

-$182,024,000 (17.52%)

-$220,683,000 (2.90%)

Net Income to Non-Controlling Interests

$0 (0%)

$0 (0%)

$0 (0%)

$0 (0%)

Net Income

-$13,580,000 (87.72%)

-$110,559,000 (39.26%)

-$182,024,000 (17.52%)

-$220,683,000 (2.90%)

Preferred Dividends Income Statement Impact

$0 (0%)

$0 (0%)

$0 (0%)

$0 (0%)

Net Income Common Stock

-$13,580,000 (87.72%)

-$110,559,000 (39.26%)

-$182,024,000 (17.52%)

-$220,683,000 (2.90%)

Weighted Average Shares

$152,449,000 (10.36%)

$138,135,000 (26.87%)

$108,876,000 (10.57%)

$98,471,000 (8.48%)

Weighted Average Shares Diluted

$152,449,000 (10.36%)

$138,135,000 (26.87%)

$108,876,000 (10.57%)

$98,471,000 (8.48%)

Earning Before Interest & Taxes (EBIT)

-$11,098,000 (89.92%)

-$110,055,000 (39.26%)

-$181,188,000 (17.15%)

-$218,706,000 (4.50%)

Gross Profit

$105,637,000 (70.55%)

$61,939,000 (17.31%)

$52,798,000 (30.93%)

$40,325,000 (-23.12%)

Operating Income

-$11,528,000 (89.58%)

-$110,615,000 (38.95%)

-$181,188,000 (17.15%)

-$218,706,000 (4.14%)

HRTX Cash Flow Statement (MRY)


Metric

2024

2023

2022

2021

Net Cash Flow from Investing

$18,714,000 (4.00%)

$17,995,000 (641.37%)

-$3,324,000 (-110.16%)

$32,729,000 (-84.34%)

Net Cash Flow from Financing

$940,000 (-98.26%)

$54,107,000 (-27.91%)

$75,059,000 (-51.89%)

$156,028,000 (1613.65%)

Net Cash Flow from Operations

-$22,529,000 (61.68%)

-$58,789,000 (59.98%)

-$146,912,000 (27.76%)

-$203,354,000 (-10.03%)

Net Cash Flow / Change in Cash & Cash Equivalents

-$2,875,000 (-121.60%)

$13,313,000 (117.71%)

-$75,177,000 (-415.02%)

-$14,597,000 (-143.91%)

Net Cash Flow - Business Acquisitions and Disposals

$0 (0%)

$0 (0%)

$0 (0%)

$0 (0%)

Net Cash Flow - Investment Acquisitions and Disposals

$20,393,000 (4.43%)

$19,527,000 (1231.34%)

-$1,726,000 (-104.83%)

$35,719,000 (-83.45%)

Capital Expenditure

-$1,679,000 (-9.60%)

-$1,532,000 (4.13%)

-$1,598,000 (46.56%)

-$2,990,000 (56.11%)

Issuance (Repayment) of Debt Securities

$0 (0%)

$24,350,000 (0%)

$0 (0%)

$148,963,000 (572834.62%)

Issuance (Purchase) of Equity Shares

$940,000 (-96.84%)

$29,757,000 (-60.36%)

$75,059,000 (962.41%)

$7,065,000 (-22.18%)

Payment of Dividends & Other Cash Distributions

$0 (0%)

$0 (0%)

$0 (0%)

$0 (0%)

Effect of Exchange Rate Changes on Cash

$0 (0%)

$0 (0%)

$0 (0%)

$0 (0%)

Share Based Compensation

$12,962,000 (-60.55%)

$32,854,000 (-23.56%)

$42,980,000 (-8.26%)

$46,851,000 (-6.70%)

Depreciation Amortization & Accretion

$2,492,000 (-14.04%)

$2,899,000 (0.35%)

$2,889,000 (-4.37%)

$3,021,000 (6.11%)

HRTX Financial Metrics (MRY)


Metric

2024

2023

2022

2021

Gross Margin

73.20% (50.00%)

48.80% (-0.41%)

49.00% (4.93%)

46.70% (-21.11%)

Profit Margin

-9.40% (89.20%)

-87.00% (48.55%)

-169.10% (33.84%)

-255.60% (0.31%)

EBITDA Margin

-6.00% (92.88%)

-84.30% (49.09%)

-165.60% (33.71%)

-249.80% (2.12%)

Return on Average Equity (ROAE)

37.40% (-90.49%)

393.20% (120.65%)

-1903.80% (-1092.11%)

-159.70% (-111.24%)

Return on Average Assets (ROAA)

-6.10% (87.94%)

-50.60% (27.71%)

-70.00% (-8.86%)

-64.30% (-17.12%)

Return on Sales (ROS)

-7.70% (91.11%)

-86.60% (48.54%)

-168.30% (33.56%)

-253.30% (1.97%)

Return on Invested Capital (ROIC)

-3.80% (90.36%)

-39.40% (38.91%)

-64.50% (21.91%)

-82.60% (11.47%)

Dividend Yield

0% (0%)

0% (0%)

0% (0%)

0% (0%)

Price to Earnings Ratio (P/E)

-17 (-700.00%)

-2.13 (-41.95%)

-1.5 (63.27%)

-4.08 (51.85%)

Price to Sales Ratio (P/S)

1.62 (-12.50%)

1.85 (-26.90%)

2.53 (-75.72%)

10.41 (-51.96%)

Price to Book Ratio (P/B)

-6.92 (7.92%)

-7.51 (-134.29%)

21.9 (82.53%)

12 (47.56%)

Debt to Equity Ratio (D/E)

-7.93 (-5.02%)

-7.55 (-143.16%)

17.49 (494.70%)

2.94 (494.14%)

Earnings Per Share (EPS)

-0.09 (88.75%)

-0.8 (52.10%)

-1.67 (25.45%)

-2.24 (10.40%)

Sales Per Share (SPS)

0.95 (2.83%)

0.92 (-6.98%)

0.99 (12.77%)

0.88 (-10.14%)

Free Cash Flow Per Share (FCFPS)

-0.16 (63.62%)

-0.44 (67.96%)

-1.36 (34.89%)

-2.1 (0.76%)

Book Value Per Share (BVPS)

-0.22 (10.16%)

-0.25 (-296.80%)

0.13 (-84.14%)

0.79 (-69.75%)

Tangible Assets Book Value Per Share (TABVPS)

1.53 (-5.09%)

1.61 (-30.11%)

2.31 (-25.76%)

3.1 (-20.28%)

Enterprise Value Over EBIT (EV/EBIT)

-35 (-775.00%)

-4 (-100.00%)

-2 (50.00%)

-4 (50.00%)

Enterprise Value Over EBITDA (EV/EBITDA)

-44.76 (-1098.42%)

-3.73 (-64.54%)

-2.27 (47.67%)

-4.34 (47.05%)

Asset Turnover

0.65 (11.51%)

0.58 (40.58%)

0.41 (64.29%)

0.25 (17.76%)

Current Ratio

2.29 (-3.55%)

2.37 (-5.05%)

2.5 (-30.31%)

3.58 (16.80%)

Dividends

$0 (0%)

$0 (0%)

$0 (0%)

$0 (0%)

Free Cash Flow (FCF)

-$24,208,000 (59.87%)

-$60,321,000 (59.38%)

-$148,510,000 (28.03%)

-$206,344,000 (-7.68%)

Enterprise Value (EV)

$385,210,215 (-3.76%)

$400,262,488 (-1.12%)

$404,787,305 (-56.74%)

$935,600,211 (-49.50%)

Earnings Before Tax (EBT)

-$13,580,000 (87.72%)

-$110,559,000 (39.26%)

-$182,024,000 (17.52%)

-$220,683,000 (2.90%)

Earnings Before Interest Taxes & Depreciation Amortization (EBITDA)

-$8,606,000 (91.97%)

-$107,156,000 (39.90%)

-$178,299,000 (17.33%)

-$215,685,000 (4.63%)

Invested Capital

$293,651,000 (-0.04%)

$293,772,000 (-5.45%)

$310,709,000 (2.34%)

$303,602,000 (78.04%)

Working Capital

$117,557,000 (7.76%)

$109,089,000 (-11.37%)

$123,080,000 (-32.88%)

$183,365,000 (-13.38%)

Tangible Asset Value

$233,147,000 (4.78%)

$222,506,000 (-11.33%)

$250,951,000 (-17.91%)

$305,706,000 (-13.53%)

Market Capitalization

$232,705,215 (-8.79%)

$255,123,488 (-14.16%)

$297,220,305 (-68.06%)

$930,670,211 (-51.60%)

Average Equity

-$36,340,500 (-29.24%)

-$28,118,000 (-394.09%)

$9,561,000 (-93.08%)

$138,187,500 (-54.06%)

Average Assets

$222,486,750 (1.85%)

$218,451,750 (-16.03%)

$260,147,750 (-24.23%)

$343,319,000 (-17.03%)

Invested Capital Average

$295,191,000 (5.58%)

$279,586,500 (-0.46%)

$280,884,750 (6.05%)

$264,854,250 (7.95%)

Shares

152,094,912 (1.35%)

150,072,640 (26.23%)

118,888,122 (16.63%)

101,935,401 (12.20%)